Cardiovascular disease remains a leading cause of illness worldwide, and researchers are exploring new ways to support heart and blood vessel function. This mini‑review article looks at the therapeutic potential of cannabigerol (CBG)—a non‑psychoactive cannabinoid from the cannabis plant—with a particular focus on its possible effects on the cardiovascular system. The authors summarize laboratory and animal studies that examine how CBG interacts with biological pathways involved in blood pressure, inflammation, oxidative stress, and vascular health.

Preclinical evidence suggests that CBG may have vasorelaxant effects, meaning it could help blood vessels relax and improve blood flow. Some studies also show that CBG and related compounds interact with the endocannabinoid system, which helps regulate cardiovascular functions such as heart rate and blood pressure. In addition, CBG appears to have anti‑inflammatory and antioxidant properties, which are important because chronic inflammation and oxidative stress contribute to the progression of heart disease. These actions may help protect blood vessel cells and support overall cardiovascular balance in animal models.

While the current findings are promising, the authors note that most of the research has been conducted in lab settings or animal studies, and much more work is needed to understand how these effects translate to humans. Larger clinical trials are necessary to determine safe and effective dosing, potential benefits, and long‑term outcomes of CBG use for cardiovascular support. Still, the review highlights CBG as a cannabinoid of interest in future heart‑health research.

Source

Comprehensive mini-review: therapeutic potential of cannabigerol – focus on the cardiovascular system. (March 2025). National Library of Medicine, National Institutes of Health.
https://pmc.ncbi.nlm.nih.gov/articles/PMC11979378/